WuXi Biologics

WuXi Biologics Releases 2023 ESG Report Demonstrating Strong Sustainability Commitment

Retrieved on: 
Tuesday, April 30, 2024
United Nations, Partnership, Water, Development, Ethics, Platinum, HK, Emerging market, Woman, Lean, Targets, Pompe, Sustainalytics, Committee, United Nations Global Compact, DEI, Climate change, UN, Carbon, Female, Science Based Targets initiative, WuXi Biologics, Student, Social, Global Compact, Region, MSCI, Wuxi, STEM, Environment, United, Patient, ESG, Lean project management, Social responsibility, Kaizen, Renewable energy

In 2023, the company joined the United Nations (UN) Global Compact, demonstrating its sustainability commitment.

Key Points: 
  • In 2023, the company joined the United Nations (UN) Global Compact, demonstrating its sustainability commitment.
  • Its significant ESG progress was recognized by major ESG rating agencies in 2023 for its progress towards reaching its commitments.
  • "As a participant of the UN Global Compact, the world's largest corporate sustainability initiative, WuXi Biologics regards sustainability as the cornerstone of its business development strategy," said Dr. Chris Chen, CEO and ESG Committee Chairman of WuXi Biologics.
  • Guided by its ESG strategy, WuXi Biologics has established strong governance mechanism, which includes oversight by the Board-level ESG Committee, guidance by the company's ESG Steering Group, and efficient implementation by the dedicated ESG department and cross-functional task forces for ESG material issues.

Global Contract Development and Manufacturing Organization Market Analysis Report 2023-2024 and 2029: Flexible and Scalable Manufacturing Processes Shaping the CDMO Landscape - ResearchAndMarkets.com

Retrieved on: 
Friday, March 22, 2024
Chemicals, Plastics, Health, Manufacturing, Other Manufacturing, Pharmaceutical, Biotechnology, Catalent, CDMO, Growth, Prevalence, Cardiovascular disease, A-DNA, Application, COVID-19, Patient, Conditional sentence, Samsung Biologics, Research, Diabetes, Messenger, WuXi Biologics, Investment, Antibody, Drug development, Workforce, API, Glaucoma, Vaccine, CMOS, Fine chemical

The global contract development and manufacturing organization (CDMO) market was valued at US$124.38 billion in 2023, and is expected to be worth US$256.90 billion in 2029.

Key Points: 
  • The global contract development and manufacturing organization (CDMO) market was valued at US$124.38 billion in 2023, and is expected to be worth US$256.90 billion in 2029.
  • The "contract development manufacturing organization (CDMO)" model has emerged in response to growing demand.
  • CDMOs, third-party providers, specialize in developing and manufacturing production processes for pharmaceutical firms, offering support throughout the drug-making journey.
  • The growing importance of specialized services, spanning early-stage development to commercial manufacturing, underscores the expanding role of CDMOs in the entire drug development lifecycle.

WuXi Biologics Named to CDP 'A List' for Water Security

Retrieved on: 
Friday, March 22, 2024
Wuxi, CDP, A List, Development, WuXi Biologics, MSCI, Disclosure, Water, Water security

SHANGHAI, March 22, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized for leadership in corporate transparency and performance on water security by the environmental non-profit CDP, securing a place on its annual 'A List'.

Key Points: 
  • SHANGHAI, March 22, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized for leadership in corporate transparency and performance on water security by the environmental non-profit CDP, securing a place on its annual 'A List'.
  • Based on data reported through CDP's 2023 questionnaire, WuXi Biologics achieved a score of 'A' in the Water Security category, ranking it in the top 2% of the more than 23,000 companies evaluated.
  • Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, "WuXi Biologics regards sustainability as the cornerstone of its business development, and we are very pleased to earn a place on the CDP's 2023 A list for Water Security.
  • It aims to further improve its corporate water management – developing new approaches and utilizing new toolkits – to promote long-term water security and generate positive impacts for the greater good of society.

WuXi Biologics Achieves Leadership Level in 2023 CDP Climate Change Assessment

Retrieved on: 
Tuesday, March 5, 2024
Climate, Climate change, CDP, Disclosure, City, Policy, Science Based Targets initiative, Energy, MSCI, WuXi Biologics, Science, Development, Politics, Environment

SHANGHAI, March 5, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized for outstanding performance in the 2023 Climate Change Assessment conducted by the global environmental non-profit CDP, achieving the Leadership level with a score of "A-".

Key Points: 
  • SHANGHAI, March 5, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized for outstanding performance in the 2023 Climate Change Assessment conducted by the global environmental non-profit CDP, achieving the Leadership level with a score of "A-".
  • In 2023, more than 23,000 companies disclosed their climate, forests and water security impacts through CDP.
  • Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, "We are very pleased to be recognized by CDP for our proactive efforts to tackle climate change.
  • In 2023, WuXi Biologics saw fruitful progress in tackling climate change.

WuXi Biologics Recognized as Both Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics

Retrieved on: 
Wednesday, February 21, 2024
United Nations Global Compact, Targets, Biophysical environment, Social, ESG, Letter, Region, Science Based Targets initiative, MSCI, WuXi Biologics, Science, Development, Corporate welfare, Research, Pharmaceutical industry

SHANGHAI, Feb. 21, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized as a 2024 Industry Top-Rated and Regional Top-Rated Company by Morningstar Sustainalytics' Environmental, Social and Governance (ESG) Ratings, marking the fourth consecutive year the company has achieved this honor.

Key Points: 
  • SHANGHAI, Feb. 21, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized as a 2024 Industry Top-Rated and Regional Top-Rated Company by Morningstar Sustainalytics' Environmental, Social and Governance (ESG) Ratings, marking the fourth consecutive year the company has achieved this honor.
  • Its 2024 ESG Ratings cover more than 14,000 companies across 42 industries worldwide, with Top-Rated Badges given to those companies with the strongest ESG achievements.
  • WuXi Biologics ranks in the top 2% of the nearly 1,000 companies assessed in the pharmaceutical sector.
  • WuXi Biologics' ESG efforts have been well recognized by global rating agencies, including an S&P Dow Jones Sustainability™ World Index listing, an MSCI AAA Rating, and an EcoVadis Platinum Medal.

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

Retrieved on: 
Thursday, January 25, 2024
WuXi Biologics, Patient, Fucose, ADCC, Vaccine

SHANGHAI, Jan. 24, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has launched WuXiaADCC PLUSTM, a superior-performing and high-yielding mammalian cell line platform for the development and manufacturing of afucosylated antibodies to elicit an enhanced ADCC response (Figure 1).

Key Points: 
  • SHANGHAI, Jan. 24, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has launched WuXiaADCC PLUSTM, a superior-performing and high-yielding mammalian cell line platform for the development and manufacturing of afucosylated antibodies to elicit an enhanced ADCC response (Figure 1).
  • The development of novel cancer therapies entails designing and engineering antibodies with increased ability to heighten the ADCC response, which is known to improve therapeutic efficacy and patient outcomes.
  • To meet growing global demand for the production of afucosylated antibodies, the WuXiaADCC PLUSTM cell line was derived from the WuXi Biologics' highly-vetted WuXiaTM cell line.
  • The WuXiaADCC PLUSTM cell line is compatible with the WuXiaTM platform process, which enables the stable production of the afucosylated antibodies at various scales for clinical and commercial manufacturing.

WuXi Biologics to Increase Manufacturing Capacity in Massachusetts

Retrieved on: 
Monday, January 8, 2024
WuXi Biologics, GMP, Patient, Laboratory, Development, Weather, Pharmaceutical industry

The added capacity will further enhance WuXi Biologics' commercial manufacturing capabilities in the U.S.

Key Points: 
  • The added capacity will further enhance WuXi Biologics' commercial manufacturing capabilities in the U.S.
  • WORCESTER, Mass., Jan. 8, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced today that it will increase the total manufacturing capacity of its facility in Worcester, Massachusetts to 36,000 liters.
  • Dr. Chris Chen, CEO of WuXi Biologics, noted, "The new commercial capacity in Worcester, Massachusetts represents a key part of our global biomanufacturing network, reflecting our commitment to continuously strengthen our capabilities in line with anticipated market and client needs.
  • We look forward to providing more efficient and cost-effective manufacturing processes and enabling our clients to bring new biologics to patients."

WuXi Biologics to Increase Manufacturing Capacity in Massachusetts

Retrieved on: 
Monday, January 8, 2024
WuXi Biologics, GMP, Patient, Laboratory, Development, Weather, Pharmaceutical industry

The added capacity will further enhance WuXi Biologics' commercial manufacturing capabilities in the U.S.

Key Points: 
  • The added capacity will further enhance WuXi Biologics' commercial manufacturing capabilities in the U.S.
  • WORCESTER, Mass., Jan. 8, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced today that it will increase the total manufacturing capacity of its facility in Worcester, Massachusetts to 36,000 liters.
  • Dr. Chris Chen, CEO of WuXi Biologics, noted, "The new commercial capacity in Worcester, Massachusetts represents a key part of our global biomanufacturing network, reflecting our commitment to continuously strengthen our capabilities in line with anticipated market and client needs.
  • We look forward to providing more efficient and cost-effective manufacturing processes and enabling our clients to bring new biologics to patients."

Myricx Bio Enters into an Exclusive Antibody License Agreement with WuXi Biologics

Retrieved on: 
Tuesday, November 21, 2023
Biology, WuXi Biologics, HER2, Imperial College London, NMT, Wuxi, Cancer, Patient, Development, ADC, Sofinnova, Francis Crick Institute, Fine chemical

Myricx intends to progress the ADC through preclinical and clinical development for difficult-to-treat solid tumours.

Key Points: 
  • Myricx intends to progress the ADC through preclinical and clinical development for difficult-to-treat solid tumours.
  • WuXi Bio will receive an upfront payment and will be eligible for development and commercialisation milestone payments, as well as royalties on net sales.
  • This is the second antibody license agreement that Myricx has entered into with a global company in the past few months as the Company builds out its pipeline of NMTi-ADCs.
  • Myricx CEO Dr Robin Carr said, “We are delighted to have reached this agreement with WuXi Bio, one of the top biologics CRDMOs globally.

WuXi Biologics Named to 2023 Dow Jones Sustainability World Index

Retrieved on: 
Tuesday, December 12, 2023
S&P Global, MSCI, AAA, DJSI, CSA, S&P Dow Jones Indices, Development, Contract research organization, Growth, United Nations Global Compact, WuXi Biologics, ESG

SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been named to the 2023 S&P Dow Jones Sustainability™ World Index (DJSI World) and DJSI Emerging Markets Index, identified as a sustainability leader by S&P Global through its Corporate Sustainability Assessment (CSA).

Key Points: 
  • SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been named to the 2023 S&P Dow Jones Sustainability™ World Index (DJSI World) and DJSI Emerging Markets Index, identified as a sustainability leader by S&P Global through its Corporate Sustainability Assessment (CSA).
  • The S&P Global CSA is an annual evaluation of companies' sustainability practices, covering more than 10,000 companies from around the world.
  • CSA results inform inclusion in the DJSI, the pioneering index family of global sustainability benchmarks available in the market.
  • Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, "We are very proud to be included in the DJSI World Index as well as the DJSI Emerging Markets Index.